BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Centessa Pharmaceuticals plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:20 pm Sale |
2024-09-30 | 13G | Centessa Pharmaceuticals plc CNTA |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-8,774,570 (Position Closed) |
Filing |
| 2024-02-14 10:13 am Purchase |
2023-12-31 | 13G | Centessa Pharmaceuticals plc CNTA |
BIOTECHNOLOGY VALUE FUND L P | 8,774,570 9.000% |
1,880,225 (+27.27%) |
Filing |
| 2022-06-16 5:24 pm Purchase |
2022-06-06 | 13G | Centessa Pharmaceuticals plc CNTA |
BIOTECHNOLOGY VALUE FUND L P | 6,894,345 7.300% |
6,894,345 (New Position) |
Filing |